

1 February 2005

The Manager Company Announcements Australian Stock Exchange 4th Floor 20 Bridge Street SYDNEY NSW 2000

Dear Sir,

Appendix 3B – Issue and Conversion of Securities

Attached is an Appendix 3B relating to the following issues of new securities in the Company:

- ✓ The conversion of 8,000,000 Class E Incentive Shares into quoted ordinary fully paid shares issued in satisfaction of the Class E milestone being the achievement of U.S. Food and Drug Administration (FDA) marketing approval for FerriScan[™]. This milestone was achieved in January 2005 with the issue subject to satisfaction of the milestone and a twelve-month escrow that has now expired.
- ✓ The conversion of 3,333,333 Class E Incentive Share Options into unquoted Options with an exercise price of 20 cents and an expiry date of 1 February 2008, converted in satisfaction of the Class E milestone being the achievement of U.S. Food and Drug Administration (FDA) marketing approval for FerriScan[™]. This milestone was achieved in January 2005 with the issue subject to satisfaction of the milestone and a twelve-month escrow that has now expired.
- ✓ The conversion of 3,333,334 Class E Incentive Share Options into unquoted Options with an exercise price of 30 cents and an expiry date of 1 February 2008, converted in satisfaction of the Class E milestone being the achievement of U.S. Food and Drug Administration (FDA) marketing approval for FerriScan[™]. This milestone was achieved in January 2005 with the issue subject to satisfaction of the milestone and a twelve-month escrow that has now expired.

Yours sincerely,

Stuart Usher Joint Company Secretary

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity

Resonance Health Limited

ABN

96 006 762 492

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	⁺ Class of ⁺ securities issued or to be issued	Options – 20 cents on or before 1/2/2008 Options – 30 cents on or before 1/2/2008	
2	Number of ⁺ securities issued or to be issued (if known) or maximum number which may be issued	3,333,333 options – 20 cents on or before 1/2/2008	
		3,333,334 options – 30 cents on or before 1/2/2008	

⁺ See chapter 19 for defined terms.

Principal terms of the ⁺ securities (eg, if options, exercise price and expiry date; if partly paid ⁺ securities, the amount outstanding and due dates for payment; if ⁺ convertible securities, the conversion price and dates for conversion)	 Unquoted Options exercisable at 20 cents on or before 1/2/2008 which entitles the holder to subscribe for one Resonance Health Ltd ordinary share upon payment of 20 cents per option. exercisable at 30 cents on or before 1/2/2008 which entitles the holder to subscribe for one Resonance Health Ltd ordinary share upon payment of 30 cents per option.
Do the ⁺ securities rank equally in all	Ordinary – yes
respects from the date of allotment with an existing ⁺ class of quoted ⁺ securities?	Options – only on exercise
 If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	
Issue price or consideration	Nil
Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issued on conversion of Class E Incentive Share Options on achievement of Milestone.
	 (eg, if options, exercise price and expiry date; if partly paid ⁺securities, the amount outstanding and due dates for payment; if ⁺convertible securities, the conversion price and dates for conversion) Do the ⁺securities rank equally in all respects from the date of allotment with an existing ⁺class of quoted ⁺securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration

7	Dates of entering ⁺ securities into uncertificated holdings or despatch of certificates	1 February 2005	
		Number	+Class
8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the securities in clause	111,353,585	Ordinary
	2 if applicable)	44,461,309	Options – 15 cents on or before 15/1/07
		20,605,194	Options – 40 cents on or before 15/1/08

⁺ See chapter 19 for defined terms.

Number	+Class
800,000	Options – 40 cents on or before 07/7/09
1,600,000	Options – 30 cents on or before 07/7/09
4,000,000	Options – 20 cents on or before 12/11/07
3,333,333	Options – 20 cents on or before 6/12/2007
3,333,333	Options – 30 cents on or before 6/12/2007
3,333,333	Options – 20 cents on or before 1/2/2008
3,333,334	Options – 30 cents on or before 1/2/2008
8,000,000	IVBH Incentive shares
	<u>IVBH Incentive</u> options
3,333,334	Options – 20 cents, 3 years from date of issue
3,333,333	Options – 30 cents, 3 years from date of issue
	800,000 1,600,000 4,000,000 3,333,333 3,333,333 3,333,333 3,333,33

Dividend policy (in the case of a trust, distribution policy) on the 10 increased capital (interests)

9

Part 2 - Bonus issue or pro rata issue


11	Is security holder approval required?	
12	Is the issue renounceable or non- renounceable?	
13	Ratio in which the ⁺ securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has ⁺ security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of ⁺ security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do tesourity holders call their	
30	How do ⁺ security holders sell their entitlements <i>in full</i> through a broker?	
31	How do ⁺ security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

⁺ See chapter 19 for defined terms.

- 32 How do ⁺security holders dispose of their entitlements (except by sale through a broker)?
- 33 ⁺Despatch date



Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities (*tick one*)
- (a) $\sqrt{}$ Securities described in Part 1
- (b) $\sqrt{}$ All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

100,001 and over

35

If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders

If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories
 1,000
 1,001 - 5,000
 5,001 - 10,000
 10,001 - 100,000

37

A copy of any trust deed for the additional ⁺securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of securities for which ⁺ quotation is sought	8,000,000
39	Class of ⁺ securities for which quotation is sought	Ordinary Shares
40	Do the ⁺ securities rank equally in all respects from the date of allotment with an existing ⁺ class of quoted ⁺ securities?	Yes
	 If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)	Conversion of 8,000,000 Class E Incentive Shares on achievement of Milestone converted into 8,000,000 ordinary fully paid shares

⁺ See chapter 19 for defined terms.

	Number	+Class
Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the	111,353,585	Ordinary
securities in clause 38)	44,461,309	Options – 15 cents on or before 15/1/07
	20,605,194	Options – 40 cents on or before 15/1/08

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those 'securities should not be granted 'quotation.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the ⁺securities to be quoted, it has been provided at the time that we request that the ⁺securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.

⁺ See chapter 19 for defined terms.

- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Iture (D

Stuart Usher Joint Company Secretary

1 February 2005

⁺ See chapter 19 for defined terms.